Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.73 |
| ▸ | BRAF | P15056 | 10/20 | 0.64 |
| ▸ | CSF1R | P07333 | 4/20 | 0.61 |
| ▸ | KIT | P10721 | 3/20 | 0.61 |
| ▸ | LCK | P06239 | 3/20 | 0.56 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799022 | 0.91 | MAPK14 (0.63) | MAPK14BRAFCSF1RKITLCK | |
| SCHEMBL6475819 | 0.84 | MAPK14 (1.00) | MAPK14BRAFRAF1MAPT | |
| SCHEMBL6528914 | 0.84 | MAPK14 (0.73) | MAPK14MAPT | |
| SCHEMBL6477474 | 0.81 | MAPK14 (0.69) | MAPK14MAPT | |
| SCHEMBL6487130 | 0.80 | BRAF (0.72) | MAPK14BRAFCSF1RKITLCK | |
| SCHEMBL6779119 | 0.78 | POLB (0.70) | MAPK14BRAFCSF1RKITLCK | |
| SCHEMBL23447716 | 0.77 | NR1H4 (0.69) | MAPT | |
| SCHEMBL19073209 | 0.77 | BRAF (0.73) | MAPK14BRAFCSF1RKITLCK | |
| SCHEMBL6487127 | 0.77 | BRAF (0.70) | MAPK14BRAFCSF1RKITLCK | |
| SCHEMBL5896949 | 0.76 | CSF1R (0.75) | MAPK14BRAFCSF1RKITLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6956037-B2 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB (SE) | 2005-10-18 | — | — | US | disclosed |
| CN-1185211-C | Benzamide derivatives for the treatment of diseases caused by cytokines | ASTRA ZENECA LTD (SE) | 2005-01-19 | — | — | CN | disclosed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | ASTRAZENECA AB | 2003-11-13 | — | — | US | disclosed |
| US-6579872-B1 | Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| EP-1077931-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca AB (SE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999059959-A1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212068-A1 | Benzamide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | MAPK14 2054/4885BRAF 1768/4885CSF1R 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.